Advertisement
Screener

Nkarta, Inc. (NKTX) EBITDA

Nkarta, Inc. (NKTX) EBITDA

  • 2026-06-30: Basis Reported; EBITDA -$40.43M; Operating income (m); Depreciation and amortization (m).
  • 2026-03-31: Basis Reported; EBITDA -$28.58M; Operating income (m); Depreciation and amortization (m).
  • 2025-12-31: Basis Reported; EBITDA -$28.66M; Operating income (m); Depreciation and amortization (m).
  • 2025-09-30: Basis Reported; EBITDA -$24.99M; Operating income (m); Depreciation and amortization (m).

Complete source-backed ebitda history.

Available history
2019-06-30 to 2026-06-30
Data captured

Historical EBITDA

EBITDA 3 month

DateBasisEBITDAOperating incomeDepreciation and amortizationRevenueEBITDA marginCapital spendingOperating cash flowCost of products and servicesResearch and developmentSelling, general and administrationIncome tax expense / benefit
2026-06-30Reported-$40.43M(m)(m)(m)(m)$183.00K*-$24.22M*(m)$29.05M(m)$0.00*
2026-03-31Reported-$28.58M(m)(m)(m)(m)$413.00K-$28.20M(m)$24.99M(m)$0.00
2025-12-31Reported-$28.66M(m)(m)(m)(m)(m)(m)(m)(m)(m)(m)
2025-09-30Reported-$24.99M(m)(m)(m)(m)-$8.00K*-$18.69M*(m)$20.20M(m)$0.00
2025-06-30Reported-$24.89M(m)(m)(m)(m)$138.00K*-$18.75M*(m)$20.78M(m)$0.00
2025-03-31Reported-$34.26M(m)(m)(m)(m)$518.00K-$29.61M(m)$24.17M(m)$0.00
2024-12-31Reported-$28.62M(m)(m)(m)(m)(m)(m)(m)(m)(m)(m)
2024-09-30Reported-$31.39M(m)(m)(m)(m)$777.00K*-$24.55M*(m)$25.25M(m)$0.00
2024-06-30Reported-$28.42M(m)(m)(m)(m)$2.35M*-$21.89M*(m)$23.13M(m)$0.00
2024-03-31Reported-$30.46M(m)(m)(m)(m)$175.00K-$28.51M(m)$25.24M(m)$0.00
2023-12-31Reported-$28.89M(m)(m)(m)(m)(m)(m)(m)(m)(m)(m)
2023-09-30Reported-$27.29M(m)(m)(m)(m)$6.19M*-$20.27M*(m)$22.19M(m)$0.00
2023-06-30Reported-$36.06M(m)(m)(m)(m)$10.33M*-$21.77M*(m)$25.12M(m)$0.00
2023-03-31Reported-$33.51M(m)(m)(m)(m)$4.82M-$20.76M(m)$26.14M(m)$0.00
2022-12-31Reported-$34.28M(m)(m)(m)(m)(m)(m)(m)(m)(m)(m)
2022-09-30Reported-$29.56M(m)(m)(m)(m)$7.67M*-$14.80M*(m)$23.43M(m)$0.00
2022-06-30Reported-$27.01M(m)(m)(m)(m)$2.63M*-$16.61M*(m)$21.05M(m)$0.00
2022-03-31Reported-$25.5M(m)(m)(m)(m)$1.77M-$18.26M(m)$19.57M(m)$0.00
2021-12-31Reported-$22.29M(m)(m)(m)(m)(m)(m)(m)(m)(m)(m)
2021-09-30Reported-$21.93M(m)(m)(m)(m)$1.52M*-$18.26M*(m)$16.62M(m)$0.00
2021-06-30Reported-$21.23M(m)(m)(m)(m)$1.38M*-$17.45M*(m)$15.96M(m)$0.00
2021-03-31Reported-$19.18M(m)(m)(m)(m)$1.03M-$14.65M(m)$13.54M(m)$0.00
2020-12-31Reported-$17.7M(m)(m)(m)(m)(m)(m)(m)(m)(m)(m)
2020-09-30Reported-$13.55M(m)(m)(m)(m)$1.63M*-$12.12M*(m)$9.83M(m)$0.00
2020-06-30Reported-$10.26M(m)(m)(m)(m)$2.49M*-$10.24M*(m)$7.86M(m)$0.00
2020-03-31Reported-$9.31M(m)(m)(m)(m)$2.33M-$8.29M(m)$7.26M(m)$0.00
2019-12-31Reported-$8.55M(m)(m)(m)(m)(m)(m)(m)(m)(m)(m)
2019-09-30Reported-$5.81M(m)(m)(m)(m)$601.20K*-$4.65M*(m)$4.62M(m)$0.00
2019-06-30Reported-$4.57M(m)(m)(m)-198042.55%(m)(m)(m)$3.62M(m)$0.00

EBITDA 12 month

DateBasisEBITDAOperating incomeDepreciation and amortizationRevenueEBITDA marginCapital spendingOperating cash flowCost of products and servicesResearch and developmentSelling, general and administrationIncome tax expense / benefit
2025-12-31Reported-$112.8M(m)(m)(m)(m)$1.21M-$88.70M(m)$90.43M(m)$0.00
2024-12-31Reported-$118.99M(m)(m)(m)(m)$4.41M-$99.70M(m)$96.74M(m)$0.00
2023-12-31Reported-$125.75M(m)(m)(m)(m)$28.15M-$86.16M(m)$96.77M(m)$0.00
2022-12-31Reported-$116.36M(m)(m)(m)(m)$47.11M-$57.00M(m)$90.90M(m)$0.00
2021-12-31Reported-$84.63M(m)(m)(m)(m)$5.03M-$67.93M(m)$63.41M(m)$0.00
2020-12-31Reported-$50.71M(m)(m)(m)(m)$7.51M-$43.51M(m)$36.22M(m)$0.00
2019-12-31Reported-$21.95M(m)(m)(m)-19086.09%$1.93M-$18.37M(m)$17.22M(m)$0.00

Similar stocks

Stock NameCountryMarket CapPE Ratio
ORAMED PHARMACEUTICALS INC. (ORMP)$0.199B1.13
Zentalis Pharmaceuticals, Inc. (ZNTL)United States$0.196B-2.48
Foghorn Therapeutics Inc. (FHTX)United States$0.213B-4.43
Eledon Pharmaceuticals, Inc. (ELDN)United States$0.219B-3.23
Whitehawk Therapeutics, Inc. (WHWK)United States$0.221B
Fortress Biotech, Inc. (FBIO)United States$0.188B0.91
ALX ONCOLOGY HOLDINGS INC (ALXO)United States$0.187B-3.52
PepGen Inc. (PEPG)United States$0.186B-1.73
AN2 Therapeutics, Inc. (ANTX)United States$0.185B-4.84
NATURES SUNSHINE PRODUCTS INC (NATR)United States$0.228B20.51